Datasets:
Javtor
/
biomedical-topic-categorization-validation

Dataset card Data Studio Files
xet
Community
PMID
int64
35.7M
36.4M
Title/Abstract
stringlengths
22
8.78k
MeshTerms
stringlengths
7
101
SemanticTypes
stringlengths
4
64
36,328,750
applic deep learn algorithm silico druggabl protein identif top prioriti drug develop identifi novel effect drug target vitro assay frequent use purpos howev tradit experiment approach insuffici larg scale explor novel drug target expens time consum labori therefor comput method emerg recent decad altern aid experiment drug discoveri studi develop sophist predict model estim unknown drugscompound target recent success deep learn dl techniqu machin learn artifici intellig attract great deal attent biomedicin field includ comput drug discoveri
D000077321
T066
36,328,749
metformin suppress vascular smooth muscl cell senesc promot autophag flux vascular smooth muscl cell vsmc senesc vasculatur result vascular age well age relat diseas metformin improv inflamm age profil enhanc autophagi howev metformin impact vsmc senesc larg undefin
D009131;D008687
T121;T024;T109
36,328,748
raman base spectrophenotyp import cell immun system human peripher blood mononuclear cell pbmcs heterogen popul cell includ b lymphocyt total number lymphocyt percentag blood marker diagnosi sever human diseas current cytometr method wide use distinguish subtyp leukocyt quantifi number techniqu use cell immunophenotyp limit number fluorochrom label antibodi appli simultan
D007963;D008214
T025
36,328,747
conserv diverg regulatori network under reproduct branch rice maiz cereal crop major sourc raw food nutrit human worldwid infloresc cereal crop reproduct organ also contribut crop product branch pattern flower plant speci determin infloresc architectur also determin grain yield good review describ grass infloresc architectur contribut final grain yield howev discuss aspect infloresc branch
D012275
T168;T002
36,328,746
telnto assist precis target chromosom segment tape perform genom larg segment experi promot annot complex genom function contribut synthesi design genom challeng obtain manipul larg complex dna sequenc high effici
D004926;D002875
T026;T007
36,328,745
engin endogen hydrogen sulfid respons smart agent photoacoust imag guid combin phototherm therapi chemotherapi colon cancer phototherm therapi synergist combin chemotherapi improv therapeut effect colon cancer howev convent therapeut agent side effect normal tissu limit applic
D061088;D006862;D003474;D003110
T121;T109;T060;T131;T197;T191;T130
36,328,744
singl cell rna sequenc analysi reveal relationship bone marrow osteopenia stz induc type diabet mice type diabet td multifactori autoimmun diseas broad knowledg genet epidemiolog clinic manag td achiev understand cell varieti bone marrow td remain limit
D003922;D003921;D001851
T047;T050
36,328,743
long term exposur ambient adult mortal nationwid cohort studi china number popul base studi investig long term effect nitrogen dioxid mortal great heterogen exist studi high popul countri asia cohort evid mortal associ extens spars
D009585;D000397
T131;T197;T069;T080
36,328,742
guard food safeti convent convers near infrar fluoresc sensor acknowledg world health organis diseas rang mild fatal link consumpt food product subject physic chemic biolog contamin nevertheless convent method common use identif health hazard foodstuff problem cope sensit requir impos latest hour regul field addit use avail wild limit aspect instrument dimens prohibit cost detect complex requir oper knowledg
D059022;D009183
T131;T109;T057
36,328,741
mscs odn load exosom immunomodulatori reveal proteom cargo sustain wound resolut non heal wound remain major burden due lack effect treatment mesenchym stem cell deriv exosom msc exo emerg therapeut option given pro regen immunomodulatori featur still littl known exact mechan mediat msc exo import modul efficaci physiolog cultur togeth load strategi continu underexplor
D055354
T026
36,328,740
structur optim honeycomb scaffold outstand abil vertic bone augment case intract dental implant requir vertic bone augment howev predict bone height volum difficult obtain vertic bone augment contact surfac scaffold bone limit bottom face scaffold furthermor strength decreas caus scaffold resorpt lead collaps augment site lead decreas bone volum height
D000540
T061
36,328,739
ubiquitin specif proteas antagon melatonin induc endocyt degrad mt receptor promot lung adenocarcinoma growth human genom encod two melatonin receptor mt mt relay melatonin signal cellular interior accumul evid link melatonin multipl health benefit among anticanc effect becom well establish howev implic receptor lung adenocarcinoma far remain incomplet understood
D008550;D000077192;D000230;D008175
T125;T121;T191;T109
36,328,731
use electromagnet field microbi process bioengin electromagnet field emf shown various stimulatori inhibitori effect microorgan year grow interest topic led numer discoveri suggest potenti applic emf biotechnolog process among observ stimul effect physic influenc result intensifi biomass product modif metabol activ pigment secret review present current state art underlin main find applic emf bioprocess practic mean process engin use exampl select studi bacteria archaea microscop fungi yeast virus microalga biolog data present concern classif emf furthermor aim highlight miss part contemporari knowledg indic weak spot approach found literatur
D004574;D058086
T070;T204
36,328,730
role psychrotroph bacteria cold activ enzym compost method adopt cold region temperatur depend compost challeng task worthi done right manner cold compost known practic sinc ancient time enough advanc overcom long mesophil phase bring compost matur short period compost process well practic discuss role psychrotroph bacteria produc cold toler hydrolyt enzym highlight chapter mechan substrat degrad elabor better understand need specif bacteria specif kind substrat allow fast effici decomposit chapter attempt pave appropri way suggest best suit method compost effici product compost conserv heat cold region
D000076282
T068;T167
36,328,728
aiee activ sensor fluoresc enhanc base detect ni live cell mechanofluorochrom photochrom properti revers sens acid base stimuli respons sensor qi qi ration develop exhibit divers featur mutabl mechanofluorochrom revers photochrom solvatochrom aggreg induc emiss enhanc aiee metal ion sens observ except structur properti relationship sensor appli revers colorimetr fluorometr determin ni low detect limit nm respect fluoresc emiss enhanc base ni sens induc chelat enhanc fluoresc chef mechan chef trigger inhibit excit state intramolecular proton transfer esipt cn isomer propos ni sens mechan investig h nmr ft ir titrat theoret studi job plot develop sensor success demonstr select acid base induc absorptionemiss switch revers ring openingclos keto enol tautomer evidenc h nmr titrat experi addit sensit sensor qi toward ni effect mimick live mcf cell industri effluent furthermor monitor ni ion also access inexpens portabl sensor coat fluoresc film final inhibit logic gate fabric imput ni edta input signal electron scrutin target ni
D003124;D008128
T078;T059
36,328,727
mxene novel cartridg n glycan enrich studi appli mxene column cartridg n glycan enrich human sampl focus analysi sialic acid linkag use derivatis protocol follow glycan analysi via matrix assist laser desorpt ionis time flight mass spectrometri maldi tof ms mxene base cartridg enrich higher number glycan ie sialyl bisect n glycan compar commerci hilic column demonstr strong potenti mxene stationari phase ms glycom analysi
D011134;D019158
T121;T123;T109
36,328,726
bioanalyt method encompass label free label tuberculosi aptasensor review high incid tuberculosi tb infect great concern world wide tradit tb diagnost techniqu ideal tb diagnosi resourc poor countri due high complex expens natur long time durat poor sensit specif well requir sophist laboratori special biosafeti condit limit major factor contribut late diagnosi tb continu persist biosensor offer sever advantag diagnost tool due independ mycobacterium tuberculosi simplic low cost high sensit specif likewis increas interest aptam biorecognit element biosensor applic lie eas synthesi modif chemic thermal stabil low cost high sensit specif toward target sever research work done mani still go fabric applic aptasensor tb diagnosi review summar label free label base electrochem piezoelectr optic aptasensor tb diagnosi publish last decad focus various aptam sequenc modif assay format sensit nanomateri enzym base signal amplif strategi possibl miniatur autom use microfluid devic
D052157;D014376;D015374;D009169;D049329
T007;T073;T075;T059;T114;T047
36,328,725
one click investig shape influenc silver nanostructur ser perform sensit detect covid sensit accur detect sar cov method meaning prevent control novel coronavirus detect techniqu support portabl onsit time onlin data transfer urgent need one click investig shape influenc silver nanostructur ser perform applic sensit detect sar cov investig achiev adjust multipl paramet concentr potenti time integr electrochem array thus various morpholog eg bulk dendrit globular spiki one click synthes ser perform result indic dendrit nanostructur superior three order magnitud signal enhanc electrod dendrit silver substrat also repres high sensit lod high reproduc rsd toward sar cov rna sequenc detect approach provid great potenti rapid diagnosi prevent divers infecti diseas
D000086382;D049329;D053768
T047;T073;T067
36,328,724
high sensit sar cov detect use graphen oxid multiplex qpcr emerg pandem sever acut respiratori syndrom coronavirus sar cov critic challeng earli accur virus diagnos howev current gold standard sar cov detect revers transcript quantit polymeras chain reaction rt qpcr report fail detect low viral load one compound graphen oxid go adsorb singl strand dna ssdna wide appli molecular pathogen detect studi present high sensit go multiplex qpcr method simultan detect two sar cov gene rdrp e one refer gene rnase p go multiplex qpcr system go pre absorb forward primer form specif go forward primer composit enter amplif system target gene amplif confin within primer enrich composit thus improv sensit assay compar convent multiplex qpcr go multiplex qpcr reduc limit detect fold copiesreact henc go multiplex qpcr assay effect use sar cov detect
D000086402;D000086382
T005;T067;T047
36,328,723
construct destruct gold nanoparticl assembl liquid liquid interfac cd sens analyt induc aggreg plasmon nanoparticl nps bulk solut wide employ optic sensor howev trace detect slow diffus kinet nps ultralow concentr analyt signific limit bind opportun analyt thus impos penalti sensit reproduc respons time sensor herein propos novel sens method two work mode base constructiondestruct np array liquid liquid interfac lli turn mode emuls state two immisc liquid phase specif bind cd cystein cys assembl nps liquid plasmon mirror lli whose reflect posit relationship concentr cd turn mode assembl np array intent destruct introduct cd aggreg neighbor nps reduc interfaci reflect compar convent bulk aggreg method singl phase nps scaveng cd aqueous phase condens onto lli boost local np concentr diffus kinet sever order prototyp achiev limit detect g l applic real life sampl
D006046;D053768
T121;T196;T073
36,328,722
enzym base amperometr biosensor year later quo vadi enzym base amperometr biosensor repres power tool remot medicin situ analysi nowaday billion peopl surround enzym base amperometr biosensor even consid relat young age year period mani research deal most target molecul earli time develop novel strategi tackl electron transfer issu realis stabl sensit select biosensor besid mark year first enzym base amperometr biosensor review aim summaris technolog advanc field main consid three enzym famili glucos oxidis enzym fructos oxidis enzym l lactat oxidis enzym overview past previous five decad current advanc electrod platform tailor technolog product applic eg situ biosensor point care poc wearabl biosensor etc focus enzym
D015374
T059;T075
36,328,721
rapid determin sar cov nucleocapsid protein base dd mxenep bioclru bpi heterojunct composit enhanc electrochemiluminesc perform end novel coronavirus diseas covid cluster atyp pneumonia caus sever acut respiratori syndrom coronavirus sar cov known high contagi diseas herein report mxenep bioclru bpi heterojunct composit construct electrochemiluminesc ecl immunosensor sar cov nucleocapsid protein covnp determin two dimension materi ultrathin phosphorus dope bismuth oxychlorid p biocl exploit first appli ecl architectur mxene act soft substrat improv properti p biocl also synergist work p biocl owe inimit set bulk interfaci properti intrins high electrochem conduct hydrophil good biocompat dd mxenep bioclru bpi exploit heterojunct composit effici signal amplifi co reaction acceler presenc tri n propylamin tpa coreact propos mxenep bioclru bpi tpa system exhibit high stabl ecl signal achiev ecl emiss quench signal recognit covnp fascin construct ecl biosensor toward covnp allow wide linear concentr rang fgml ngml low limit detect lod fgml sn furthermor present strategi shed light design high effici ecl nanostructur combin mxene architectur semiconductor materi field nanomedicin ecl biosensor success detect covnp human serum promot prosper develop diagnost method sar cov
D015374;D000086382
T047;T067;T059;T075
36,328,720
facil one step synthesi graphen oxidepolyhedr oligomer silsesquioxan composit coat fiber high effici solid phase microextract polycycl musk effici fabric excel fiber coat high perform solid phase microextract spme interest high effici synthesi strategi graphen oxidepolyhedr oligomer silsesquioxan goposs composit coat fiber exploit via ultra fast uv polymer one step appli excel spme polycycl musk pcms use methacryloxi siloxan graft go poss methacryl substitut poss function monom facil direct uv polymer multipl reaction includ alkenyl radic reaction thiol ene click chemistri fulfil thiol pretreat fiber min without tedious process characterist morpholog ft ir xps bet tg fiber coat studi detail well spme perform attribut rigid stereo conform poss larg conjug plane go base nanosheet signific surfac area high hydrophob intrins interact adopt fiber coat comparison commerci spme fiber poss base go base spme fiber superior extract perform toward pcms achiev goposs coat fiber high effici extract pcms gain promin enrich factor sensit detect limit pcms ngl particular extract effici robust still maintain high level pcms even cycl applic good recoveri pcms reach river water cosmet sampl respect light attract approach effici fabric robust goposs coat fiber high perform spme pcms
D052617;D006108
T196;T059;T109
36,328,719
evolut natur dihydroptero synthas develop signal amplifi fluoresc method detect sulfonamid milk studi recognit mechan affin natur dihydroptero synthas sulfonamid studi respect key contact amino acid ser mutat arg use site direct mutagenesi method produc mutant result show bind energi affin drug general improv mutant use recognit reagent develop direct competit fluoresc method well micropl determin drug milk due use signal amplifi fluoresc tracer limit detect drug rang ngml sensit improv fold comparison convent fluoresc tracer comprehens comparison present method show general better perform previous report immunoassay sulfonamid therefor method could use effici tool routin screen sulfonamid residu larg number food sampl
D004094;D008892
T168;T126;T116;T031
36,328,718
review develop applic surfac molecular imprint polym toward amino acid peptid protein molecular imprint polym mip receiv wide interest bioanalysi field artifici antibodi mimic biolog receptor select recogn adsorb target molecul owe specif affin target tradit mip obtain bulk imprint defect includ low adsorpt capac poor site access restrict mass transfer irregular morpholog limit develop surfac molecular imprint polym smip show featur larg surfac area allow fast mass transfer high adsorpt capac effici intens use research amino acid peptid protein due advantag review systemat summar prepar smip includ compon polymer strategi applic focus amino acid peptid protein discuss detail final futur trend challeng design develop smip describ
D054802
T063
36,328,717
recent advanc airborn pathogen detect use optic electrochem biosensor world current face advers condit due pandem airborn pathogen sar cov prevent better cure thus rapid detect airborn pathogen necessari reduc outbreak save mani live consid immens role divers detect techniqu airborn pathogen proper summar techniqu would benefici human henc review explor summar emerg techniqu optic electrochem biosensor use detect airborn bacteria bacillus anthraci mycobacterium tuberculosi staphylococcus aureus streptococcus pneumonia virus influenza avian influenza norovirus sar cov signific first section briefli focus various diagnost modal appli toward airborn pathogen detect next fabric optic biosensor use various transduc materi involv colorimetr fluoresc strategi infecti pathogen detect extens discuss third section well document base electrochem biosensor airborn pathogen detect differenti puls voltammetri cyclic voltammetri squar wave voltammetri amperometri imped spectroscopi uniqu pros con modal futur perspect address fourth fifth section overal review inspect research articl publish last decad persuad import optic electrochem biosensor airborn pathogen detect
D000086382;D015374
T075;T047;T059;T067
36,328,716
metal organ framework separ review possibl design high permeabl select metal organ framework mof design function larg number possibl mof structur permut aris consider number possibl metal node great varieti organ ligand use materi herein discuss applic mof manner separ includ gas adsorptionsepar membran gas chromatographi gc liquid chromatographi lc water harvest computermachin learn design mof applic requir mof specif structur motif relev properti includ polar temperatur stabil solvent stabil pore size pore volum surfac area etc mof use adsorpt separ gase quit differ use membran technolog chromatograph stationari phase area chromatographi far report gc separ lc also consider effort develop mof chiral stationari phase henc addit chiral compon ad mof support cyclodextrin various amino acid mof use general adsorb inorgan organ molecul uniqu mof applic involv water harvest shown potabl water made arid environ select adsorb water vapor air even low humid mof could import analyt applic well final new focus autom design mof desir properti specif task use comput design machin learn briefli cover final section review
D000073396
T109
36,328,715
review chromatograph specif detect methodolog unravel complex moah food contamin food miner oil hydrocarbon particular miner oil aromat hydrocarbon moah potenti pose health hazard consum howev identifi toxic substanc among mani thousand compound compris miner oil food sampl difficult analyt challeng accord european food safeti author lack concentr structur data miner oil hydrocarbon food therefor clear extent consum europ might expos toxic level moah current gold standard method determin miner oil hydrocarbon onlin high perform liquid chromatographi lc gas chromatographi gc flame ionize detect quantifi total saturatedaromat content give qualit inform object review explor futur prospect miner oil hydrocarbon determin moah character food end peer review literatur explor particular viewpoint methodolog detail character moah fraction aid toxicolog assess literatur clear show much gain orthogon power multidimension chromatograph separ mass spectrometr ms detect comprehens two dimension gc coupl ms preced pre fraction moah lc suggest promis approach research addit strength weak number altern approach qualit quantit analysi discuss
D008899;D006841
T121;T109
36,328,706
orexin reserv mechanist framework role orexin hypocretin addict propos orexin signal transform motiv relev state adapt behavior direct toward exploit opportun manag threat process refer motiv activ advanc anim model sinc permit higher resolut measur motiv state particular behavior econom approach studi drug demand character condit lead enhanc motiv under addict motiv plastic parallel persist increas orexin express topograph specif manner find confirm across speci includ human normal orexin level also reduc drug motiv addict model new advanc lead us updat propos framework orexin function propos capac orexin neuron exhibit dynam shift peptid product contribut role adapt motiv regul achiev via pool reserv orexin neuron reserv normal bidirect recruit permit motiv plastic promot flexibl adapt behavior patholog state addict howev propos orexin system lose capac adapt adjust peptid product result focus hypermotiv drug driven aberr persist high express orexin reserv pool mechanist framework implic understand treatment sever psychiatr disord beyond addict particular character motiv dysfunct
D009479;D016739
T123;T116;T048
36,328,694
coronari arteri bypass surgeri without saphen vein graft jacc review topic week approxim patient age undergo contemporari coronari bypass surgeri receiv least saphen vein graft svg recogn svg develop progress acceler atherosclerosi result stenosi occlus occur year postop arteri conduit littl evid progress failur svg could avoid svg total arteri revascular tar lead differ late year surviv literatur review studi n match patient mean year postop found reduc caus mortal tar hr ci p expand analysi new unpublish data set n match patient combin literatur review n found reduc caus mortal tar hr ci p addit bayesian analysi found high probabl tar associ reduct caus mortal
D012501;D001026
T061;T023
36,328,690
risk factor hospit cardiac arrest patient st segment elev myocardi infarct hospit cardiac arrest ihca one deleteri complic st segment elev myocardi infarct stemi
D000072657;D054058;D062645;D058687
T061;T047;T046
36,328,672
xpm enhanc exogen data visibl process mine well establish disciplin applic mani industri sector includ healthcar date public consid context process execut littl consider given contextu data exogen data practic includ process mine analysi beyond includ case event attribut typic event log show combin process data endogen exogen data generat insight possibl standard process mine techniqu contribut framework process mine exogen data new analys exogen data process behaviour link process outcom new analys visualis exogen data highlight trend variat show overlap distinct exist outcom appli analys healthcar set show clinician could extract insight differ patient vital sign exogen data relev clinic outcom present two evalu use public avail data set mimic iii demonstr applic analysi evalu show process mine integr larg amount physiolog data intervent result discrimin convers clinic interpret inform
D003695;D057225
T058;T066;T093
36,328,671
cyclegan virtual stain transfer see realli believ digit patholog area prone high variat due multipl factor strong affect diagnost qualiti visual appear whole slide imag wsis state art method deal variat tend address style transfer inspir approach usual solut direct appli success approach literatur potenti task relat modif major obtain result visual convinc howev paper show guarante imag direct use either medic diagnosi reduc domain shiftthi articl show slight modif stain transfer architectur choic normalis layer result varieti visual appeal result surpris great effect abil stain transfer model reduc domain shift extens qualit quantit evalu confirm translat result differ stain transfer architectur distinct real sampl therefor conclus made visual inspect pretrain model evalu might mislead
D004396;D007091
T197;T130;T066;T109
36,328,670
cardiac anomali detect consid addit nois convolut distort model heart sound record cardiac auscult essenti point care method use earli diagnosi heart diseas automat analysi heart sound abnorm detect face challeng addit nois sensor depend degrad paper aim develop method address cardiac abnorm detect problem compon present cardiac auscult sound first mathemat analyz effect addit nois convolut distort short term mel filterbank energi base featur convolut neural network cnn layer base analysi propos combin linear logarithm spectrogram imag featur featur provid input residu cnn network resnet heart sound abnorm detect experiment valid perform first open access multiclass heart sound dataset analyz effect addit nois mix lung sound nois record noisi condit propos method outperform one best perform method literatur achiev macc mean sensit specif averag f score respect averag nois level next perform heart sound abnorm detect binari classif experi physionetcinc challeng dataset involv noisi record obtain multipl stethoscop sensor propos method achiev signific improv result compar convent approach dataset presenc addit nois channel distort area roc receiv oper characterist curv auc f score macc also show propos method show best mean accuraci across differ sourc domain includ stethoscop nois variabl demonstr effect differ record condit propos combin linear logarithm featur along resnet classifi effect minim impact background nois sensor variabl classifi phonocardiogram pcg signal method thus pave way toward develop comput aid cardiac auscult system noisi environ use low cost stethoscop
D012815;D006347
T066;T042
36,328,669
manifesto explain artifici intellig medicin rapid increas interest use artifici intellig ai comput applic rais parallel concern abil lack thereof provid understand explain output user concern especi legitim biomed context patient safeti paramount import posit paper bring togeth seven research work field differ role perspect explor depth concept explain ai xai offer function definit conceptu framework model use consid xai follow seri desiderata attain explain ai touch upon key domain biomedicin
D001185;D008511
T090;T091;T073;T066
36,328,668
tempor deep learn framework retinopathi predict patient type diabet adopt electron health record hospit ensur avail larg dataset use predict medic complic trajectori patient real world set high variabl make longitudin data model challeng recent year signific progress made studi deep learn model appli time seri howev applic model irregular medic time seri imt remain limit address issu develop generic deep learn base framework model imt facilit compar studi sequenti neural network transform long short term memori irregular time represent techniqu valid studi predict retinopathi complic conduct patient type diabet french databas use histor glycosyl hemoglobin measur without data aggreg imput transform base model combin soft one hot represent time gap achiev highest score area receiv oper characterist curv specif sensit improv architectur without time inform first attempt predict retinopathi complic patient type diabet use deep learn longitudin data collect patient visit studi highlight signific model time gap medic record improv predict perform util generic framework conduct extens compar studi
D000077321;D003922;D012164
T047;T066
36,328,667
weak supervis learn use attent gate colon cancer histopatholog imag segment recent artifici intellig name deep learn method revolution wide rang domain applic besid digit patholog far play major role diagnosi prognosi tumor howev characterist whole slide imag name gigapixel size high resolut shortag rich label sampl hinder effici classic machin learn method goe without say tradit method poor general differ task data content regard success deep learn deal larg scale applic resort use model histopatholog imag segment task first review compar classic unet att unet model colon cancer wsi segment spars annot data scenario introduc novel enhanc model att unet differ scheme propos skip connect spatial attent gate posit network fact spatial attent gate assist train process enabl model avoid irrelev featur learn altern presenc modul name alter attunet model add robust ensur better imag segment result order cope lack rich annot data aicolo colon cancer dataset suggest use multi step train strategi also deal wsi spars annot unbalanc class issu propos method outperform state art approach alter attunet generat best compromis accur result light network model achiev accuraci spars aicolo colon cancer dataset final evalu valid propos architectur resort public avail wsi data nct crc k crc warwick colon cancer histopatholog dataset respect accuraci reach comparison state art approach establish view compar key solut histopatholog imag segment
D007091;D003110
T191;T066
36,328,666
evolutionari optimis antibiot dose regimen bacteria differ level resist antimicrobi resist one biggest threat global health food secur develop antibiot overus misus main driver emerg resist crucial optimis use exist antibiot order improv medic outcom decreas toxic reduc emerg resist formul design antibiot dose regimen optimis problem use evolutionari algorithm suit continu optimis differenti evolut solv regimen repres vector real number encod daili dose vari across treatment durat stochast mathemat model bacteri infect tuneabl resist level use evalu effect evolv regimen object minimis treatment failur rate subject constraint maximum total antibiot use consid simul differ level bacteri resist two way administ drug oral intraven well coinfect two strain bacteria approach produc effect dose regimen averag improv lower failur rate compar standard fix daili dose regimen total amount antibiot
D000900;D001424
T121;T047;T195
36,328,655
finerenon heart failur outcom kidney functionalbuminuria chronic kidney diseas diabet patient type diabet td risk cardiovascular mortal heart failur hf increas decreas kidney function estim glomerular filtrat rate egfr increas albuminuria urin albumin creatinin ratio uacr finerenon select nonsteroid mineralocorticoid receptor antagonist improv cardioren outcom patient chronic kidney diseas ckd td fidel finerenon chronic kidney diseas type diabet combin fidelio dkd figaro dkd trial programm analysi
D003924;D006333;D051436
T047;T046
36,328,654
trend heart failur relat mortal among older adult unit state us popul age concurr increas heart failur hf burden howev hf relat mortal trend among adult year investig
D006333
T047;T046
36,328,653
steroid mra across spectrum renal function pool analysi rcts mineralocorticoid receptor antagonist mras underus patient kidney dysfunct efficaci among patient chronic kidney diseas ckd uncertain
D006947;D006333;D051436
T033;T047;T046
36,328,651
posterior wall thick associ surviv follow septal myectomi obstruct hypertroph cardiomyopathi left ventricular lv posterior wall thick pwt predictor sudden cardiac death pediatr patient hypertroph cardiomyopathi hcm prognost import pwt adult examin
D006333;D002312
T047;T046
36,328,649
risk depress suicid diagnosi heart failur nation cohort studi heart failur hf associ psychosoci distress long term mental health sequela unclear
D006333;D013405
T033;T047;T046
36,328,647
trend ischem evalu new onset heart failur without known coronari arteri diseas guidelin recommend consider ischem evalu class iia iib new onset heart failur hf well known often perform lead revascular
D003324;D006333;D062645
T061;T047;T046
36,328,645
famili screen dilat cardiomyopathi preval incid potenti limit follow accord pattern inherit incomplet penetr fewer half relat dilat cardiomyopathi proband develop diseas
D002311;D006333
T047;T046
36,328,644
retin microvasculatur potenti window heart failur prevent endotheli dysfunct microvascular diseas shown play import role develop progress heart failur hf retin imag provid uniqu opportun noninvas assess vascular structur function vessel featur microcircul within retina accumul evid suggest retin vessel calib microvascular featur vascular characterist extract various imag modal associ alter left ventricular structur function stage b hf well incid develop symptomat hf general popul moreov dynam retin vessel analysi shown differenti hf patient base phenotyp given increas avail rapid imag acquisit devic eg nonmydriat widefield system smartphon base retin camera integr artifici intellig base interrogationassess techniqu retin imag promis noninvas tool conjunct cardiac imag biomark prevent hf risk stratifi risk develop hf review focus current evid retin microvasculatur chang potenti clinic relev promis util retin imag hf
D006333
T047;T046
36,328,636
support care patient critic coronavirus diseas specif therapi treatment coronavirus diseas covid limit efficaci event patient worsen clinic requir admiss intens care unit icu thus provid qualiti support care essenti overal manag patient critic covid patient respiratori failur requir intub support noninvas posit pressur ventil continu posit airway pressur high flow oxygen use respiratori modal may prevent patient subsequ requir intub basic compon support care critic ill appli equal patient covid icu
D000086382;D063087;D012131
T061;T047;T046;T067
36,328,635
manag sever critic covid infect immunotherapi follow reduct mortal demonstr dexamethason treatment sever covid mani target immunotherapi investig thus far inhibit il jak pathway robust data grant emerg use author treatment sever diseas howev must note critic ill patient compris relat small proport trial covid therapeut despit bear disproportion burden morbid mortal furthermor rapid fluiditi clinic trial conduct pandem set contribut difficulti extrapol avail trial data critic ill patient exclus mani patient requir invas mechan ventil preponder ordin scale base endpoint frequent lack blind particular challeng data need identifi benefici treatment complex milieu critic ill covid infect
D000086382
T047;T067
36,328,628
critic care vascular surgeri patient patient requir major vascular surgeri suffer widespread atherosclerosi multipl comorbid place increas risk postop complic requir admiss intens care unit icu postop critic care patient focus hemodynam optim earli identif manag complic improv outcom
D003422;D007362
T058;T073;T093
36,328,626
unstabl carotid plaqu carotid revascular perform prevent cerebrovascular event patient symptomat asymptomat high degre carotid stenosi oper carri signific risk periop stroke care select patient benefit procedur essenti certain plaqu characterist includ textur associ increas tendenc ruptur use identifi high risk patient medic therapi carotid endarterectomi carotid stent mainstay patient manag care select patient anesthesia techniqu general anesthesia monitor anesthesia care region anesthesia use safe revascular procedur
D016894;D016893;D020521;D000765
T061;T047;T020
36,328,625
anesthet manag endovascular repair thorac abdomin aortic aneurysm aortic aneurysm abdomin thorac signific caus death disabl unit state endovascular aneurysm repair sinc becom prefer oper treatment thorac abdomin aneurysm lower rate complic better outcom compar open approach patient present endovascular aneurysm repair often comorbid condit relat aortic patholog condit evalu optim procedur
D017544;D019917;D057510;D000777
T061;T121;T047;T039
36,328,622
thorac thoracoabdomin aneurysm etiolog epidemiolog natur histori thorac aortic aneurysm thoracoabdomin aneurysm often found incident complic includ dissect ruptur thorac aortic aneurysm thoracoabdomin aneurysm develop patient risk factor atherosclerosi younger patient without signific cardiovascular risk factor may genet basi includ syndrom marfan ehler danlo loey dietz bicuspid aortic valv thorac aneurysm grow slowli time factor acceler growth rate includ dissect aneurysm size bicuspid valv diseas marfan syndrom size cutoff complic occur determin surgeri intervent consid
D017545;D000784;D008382;D006349
T047;T046
36,328,621
abdomin aortic aneurysm etiolog epidemiolog natur histori abdomin aortic aneurysm potenti lethal condit decreas frequenc tobacco use declin exact etiolog remain unknown smoke perturb seem trigger inflammatori state tunica media male sex advanc age clear demograph risk factor develop abdomin aortic aneurysm natur histori diseas vari screen remain vital rare diagnos physic examin elect repair common done endovascular offer signific morbid mortal advantag emerg intervent aortic ruptur
D017544;D001019
T047
36,328,620
monitor vascular surgeri vascular surgic patient present uniqu challeng anesthesiologist medic vulner well tendenc rapid intraop hemodynam chang intraop monitor use decad reduc advers outcom improv mortal creat optim surgic condit understand indic appropri manag monitor modal essenti optim patient care prevent harm associ misinterpret aim review monitor technolog use complex vascular procedur well current guidelin clinic trial outcom basic mechan monitor modal
D016343;D014656
T060;T061
36,328,617
complic vascular diseas vascular diseas sequela increas periop risk noncardiac surgic patient review author discuss vascular diseas epidemiolog pathophysiolog risk stratif manag strategi reduc advers periop outcom
D011183;D014652
T047;T046
36,328,616
preoper evalu cardiac risk assess vascular surgeri summar epidemiolog trend outcom preoper guidelin vascular surgeri patient vascular surgeri continu evolv technolog engin treat surgic popul suffer high preval comorbid preoper optim seek character burden diseas achiev medic control timelin avail surgeri risk assess evalu optim predict major advers cardiac event evolv scienc vascular surgeri qualiti initi made impact ongo investig may demonstr valu preoper echocardiographi function capac frailti mobil assess
D011300;D000073496
T033;T184;T058;T046
36,328,612
advanc treatment neonat biliari diseas articl discuss current standard care neonat biliari diseas particular manag biliari atresia choledoch cyst highlight surgic consider guidelin adjuv therapi promis therapeut option investig
D015529;D001656;D007232
T019;T047
36,328,611
advanc manag neonat born anorect malform anorect malform occur children present mark varieti type sever malform diagnos earli neonat period antenat diagnosi remain relat elus follow diagnosi accur assess focus manag crucial reduc potenti morbid mortal review focus investig manag newborn anorect malform introduct novel assess tool complex malform type
D000071056
T019;T190
36,328,610
review necrot enterocol spontan intestin perfor clinic present treatment outcom necrot enterocol surgeri trial nest highlight import distinguish necrot enterocol nec spontan intestin perfor sip develop surgic treatment plan research need increas accuraci distinct even current abil initi laparotomi appear optim infant presum nec prefer initi oper sip equivoc rate nec like decreas slowli wherea sip new imag modal especi ultrasound becom use requir detail investig understand mechan caus two condit remain paramount import
D020345;D007416;D007235;D007232
T047
36,328,609
abdomin wall defect review current practic guidelin common congenit abdomin wall defect gastroschisi omphalocel gastroschisi defect abdomin wall expos abdomin content mortal rate low length stay often prolong bowel dysmotil intestin abnorm complic case omphalocel defect umbil cord herniat abdomin content cover sac associ genet abnorm anomali lead signific morbid mortal prenat diagnosi condit allow improv prenat consult coordin perinat care improv clinic outcom
D020139;D006554;D034861
T019;T047;T023
36,328,606
surgic manag congenit diaphragmat hernia congenit diaphragmat hernia cdh challeng surgic diseas requir complex preoper periop postop care surviv depend success reduct repair defect numer complex decis must made regard time prepar surgeri review describ challeng controversi inher surgic cdh care provid recommend manag base recent evid
D065630;D015199
T061;T019
36,328,604
utero therapi congenit diaphragmat hernia congenit diaphragmat hernia anomali often prenat diagnos span wide spectrum diseas high morbid mortal associ fetus sever defect congenit diaphragmat hernia thus ideal target fetal intervent review literatur prenat diagnosi describ histori fetal intervent congenit diaphragmat hernia discuss fetal endoscop tracheal occlus tracheal occlus acceler lung growth trial result final present preclin studi potenti futur direct
D065630;D005315;D046128
T061;T019;T047
36,328,603
fetal therapi renal anhydramnio sever form congenit anomali kidney urinari tract present fetal life earli pregnanc renal anhydramnio consid lethal due pulmonari hypoplasia without fetal therapi due high rate addit structur anomali genet abnorm associ syndrom detail anatom survey genet test imper stratifi pregnanc appropri fetal intervent restor amniot fluid around fetus princip goal prenat treatment ongo multi center renal anhydramnio fetal therapi raft trial assess safeti efficaci serial amnioinfus prevent pulmonari hypoplasia under renal diseas address
D016104;D046128
T061;T046
36,328,602
fetal repair neural tube defect myelomeningocel common congenit neurolog defect nonleth diseas address fetal surgeri random control trial establish amelior arnold chiari ii malform reduc ventriculoperiton shunt rate improv distal neurolog function patient receiv utero repair long term follow school age children demonstr persist effect use stem cell fetal repair investig improv distal motor function
D008591;D009436;D046128
T061;T019;T047;T020
36,328,600
molecular cellular utero therapi signific advanc matern fetal medicin gene sequenc technolog foster new frontier utero molecular cellular therapeut includ gene edit enzym replac therapi stem cell transplant treat singl gene disord limit postnat treatment strategi utero therapi take advantag uniqu development properti fetus allow correct monogen disord irrevers diseas patholog develop earli preclin studi anim model encourag studi need evalu safeti efficaci prior widespread clinic use
D046128;D018380
T061
36,328,599
rear matern fetal surgeri matur field concept adulthood matern fetal surgeri fraught inher controversi within medic communiti general public despit challeng field matern fetal surgeri evolv intern enterpris care nurtur pioneer foresight resili field navig ethic dilemma rigor scientif methodolog collabor transpar accord central pillar consist throughout brief moment histori matern fetal surgeri serv catalyst success matur fetal intervent exemplar technolog innov propel clinic innov well celebr master delic balanc caution optim
D004992;D046128
T078;T061
36,328,595
myeloma immunoglobulin rearrang transloc detect target captur sequenc multipl myeloma plasma cell neoplasm character clonal immunoglobulin v j signatur oncogen immunoglobulin gene transloc addit subclon genom chang acquir myeloma progress therapeut select pcr base method detect v j rearrang bias introduc high multiplex reaction primer undermin somat hypermut readili extend includ mutat detect report hybrid captur approach capig seq target end v j segment immunoglobulin loci enabl effici detect v j rearrang also includ bait oncogen transloc mutat detect demonstr complet concord match whole genom sequenc andor pcr clonotyp cell line report clonal sequenc uncharacter cell line also demonstr applic patient specimen includ bone marrow cell free dna sampl capig seq show concord bone marrow cfdna blood sampl contemporan follow regard somat variant v j transloc detect capig seq novel effici approach examin genom alter myeloma
D009101
T191
36,328,587
ultra magnifi imag thoracoscop biopsi specimen use ex vivo endocytoscopi three patient mesothelioma perform endocytoscopi ec ex vivo evalu mesothelioma specimen biopsi medic thoracoscopi three patient evalu biopsi specimen base densiti nuclei irregular nuclei shape use ec compar histopatholog find specimen consid malign base ec diagnos malign base histopatholog nine specimen evalu non malign base ec consist six specimen diagnos malign base histopatholog three diagnos non malign base histopatholog ec feasibl util ex vivo ultra magnifi imag thoracoscop biopsi specimen patient mesothelioma
D008654;D000086002;D010997
T191
36,328,586
endoscop submucos dissect improv bloodi stool associ polypoid type mucos prolaps syndrom case seri mucos prolaps syndrom mps benign inflammatori diseas rectum caus bloodi stool endoscop treatment mps establish herein report consecut case seri endoscop submucos dissect esd mps four case treat esd alon lesion dentat line polypoid median procedur time minut complic observ median observ period day bloodi stool endoscop recurr mps observedesd polypoid type mps effect treatment improv bloodi stool suppress endoscop recurr
D000069916
T061
36,328,585
reduc rate diseas flare japanes patient system lupus erythematosus alter balanc use glucocorticoid immunosuppress recent decad object studi examin whether diseas control japanes patient system lupus erythematosus sle improv recent year possibl associ alter balanc use glucocorticoid immunosuppress method enrol japanes patient sle visit medic center group patient compar patient encount group b patient overlap group patient background characterist dose glucocorticoid use immunosuppress time sle onset diseas flare review medic record diseas flare defin new british isl lupus assess group b score least one system result lupus nephriti neuropsychiatr manifest less frequent observ group group b p p respect although initi glucocorticoid dosag similar group inclus rate immunosuppress initi sle treatment signific higher group group b vs group b p median number sle flare per person year signific lower group group b vs respect p propens score match analysi indic associ sle flare non use immunosuppress initi treatment p rate infecti diseas complic similar group conclus recent aggress use immunosuppress japan result reduct rate sle flare
D005938;D008180
T125;T047;T039;T109
36,328,584
differ prognost factor among patient hospit heart failur accord age categori kuniumi registri acut cohort object previous studi describ sever prognost factor heart failur hf howev result deriv registri consist convent age group might repres increas age societi present studi explor prognost factor caus death hospit patient hf across differ age categori use acut hf registri includ relat old patient method total consecut patient hf patient enrol divid patient group year old evalu caus death prognost factor caus death result mean follow period day patient caus death kaplan meier analysi demonstr signific higher incid caus death elder group younger group log rank p cox proport hazard regress analysi reveal presenc atrial fibril hazard ratio hr confid interv ci p notabl predict factor caus death year old group wherea clinic frailti scale score hr ci p year old group conclus atrial fibril notabl predictor hf young patient wherea frailti low grade albuminemia essenti predict factor hf elder patient increas number elder patient hf comprehens multidisciplinari treatment necessari
D001281;D000073496;D006333
T033;T184;T047;T046
36,328,583
assess carotid atherosclerot plaqu among young patient famili hypercholesterolemia object data exist regard atherosclerot chang occur among patient famili hypercholesterolemia fh carotid ultrasonographi non invas method evalu issu present studi compar clinic util carotid intima media thick cimt carotid plaqu score cps estim onset progress carotid atherosclerosi among patient heterozyg fh hefh method retrospect analyz patient year old underw carotid ultrasonographi hospit classifi hefh group n year old non fh group n year old base clinic diagnosi compar cimt cps valu addit estim onset progress carotid atherosclerosi among young hefh patient result signific differ cimt hefh non fh group mm vs mm p contrast cps signific higher hefh group non fh group vs p regress equat cps hefh group x r p conclus assess base cps rather cimt appear better captur progress carotid atherosclerosi among young hefh patient carotid atherosclerosi may start develop year old patient hefh
D058226;D006938;D002340
T047;T046;T020;T031
36,328,582
factor contribut prognosi second line therapi ramucirumab advanc hepatocellular carcinoma object multipl therapeut agent exist advanc hepatocellular carcinoma hcc prognost factor second line subsequ therapi unclear ramucirumab molecular target agent effect hepatocyt alpha fetoprotein afp ngml sorafenib failur examin prognost factor efficaci ramucirumab prior therapi sorafenib method retrospect multicent studi patient treat ramucirumab hcc prior therapi sorafenib includ patient receiv line ramucirumab analyz background factor liver reserv prognosi treatment durat efficaci result median albumin bilirubin albi valu show littl chang ramucirumab treatment albi valu improv patient prognos better improv respons efficaci rate high reach studi similar limit patient ngml afp thirteen patient receiv treatment ramucirumab failur signific better prognosi ramucirumab administr also signific better prognosi start first tyrosin kinas inhibitor receiv treatment univari multivari analys prognost factor continu treatment anoth drug ramucirumab failur good albi valu initi signific presenc ramucirumab respons treatment durat associ prognosi good albi valu initi albi valu improv treatment also identifi independ factor associ elig treatment ramucirumab failur treatment line correl avail treatment anoth drug treatment failur conclus albi valu improv ramucirumab treatment allow subsequ treatment failur improv overal prognosi
D006528;D008113
T191
36,328,541
clinicopatholog immunophenotyp featur dog presumpt larg granular lymphocyt leukaemia larg granular lymphocyt leukaemia lgll describ rang speci common report human dog speci neoplasia exhibit divers phenotyp biolog behaviour phenotyp partial predict behaviour current littl knowledg concurr haematolog serum biochemistri featur concurr occurr distinct neoplasia canin lgll case studi present canin case seri defin haematolog paramet novel serum biochemistri find phenotyp larg granular lymphocyt australian case seri neutrophilia common haematolog abnorm identifi dog dog biochemistri data avail elev serum gamma glutamyl transferas five dog studi exhibit concurr neoplasia period studi demonstr relat common clinic outcom canin lgll case agreement previous canin human studi common lgll phenotyp dog cd cd cd work need defin variabl predict biolog behaviour lgll dog
D054066;D004283
T047;T191
36,328,540
effici correct pcr quantif identif preval load respiratori diseas caus agent feedlot cattl bovin respiratori diseas brd preval diseas feedlot cattl worldwid bovin alphaherpesvirus boahv histophilus somni mannheimia haemolytica mycoplasma bovi pasteurella multocida trueperella pyogen accept common etiolog agent associ brd although agent common upper lower airway clinic brd case also exist normal flora suggest presenc upper airway alon necessarili inform respect diseas status risk determin relationship presenc load diseas status investig relationship load upper airway induct activ brd case feedlot cattl use effici correct pcr quantif approach abl accur determin preval load key brd agent upper respiratori tract show cattl hospit pen higher preval load agent singl combin compar cattl sampl feedlot induct combin agent accur indic brd risk cattl four agent detect upper airway like undergo treatment brd non brd ailment addit bovi rare detect feedlot induct identifi high preval cattl hospit pen find present potenti new technolog approach investig analysi identif brd associ viral bacteri agent australian feedlot system well brd diseas manag treatment
D016978;D002418;D048090
T047;T007
36,328,470
e cigarett tobacco product use among nys youth state wide vape flavour restrict polici reduc youth e cigarett use new york state nys public health prioriti may state wide restrict flavour e cigarett except tobacco flavour pass studi examin chang nicotin product use behaviour among youth around time state wide vape flavour restrict
D000072137;D066300;D014029;D062789
T073;T109;T055;T131;T048
36,328,469
remov mango flavour juul pod creat opportun adulter mango juul compat pod alter chemic constitu juul lead electron cigarett e cigarett brand usa novemb juul pre emptiv limit onlin store sale non tobacco menthol flavour pod ahead impend flavour ban sinc remov sale mango flavour juul compat pod introduc market smaller compani aim studi compar chemic constitu origin juul mango pod mango flavour juul compat pod
D066300;D031022;D000072137;D062789
T073;T109;T168;T055;T131;T002
36,328,467
chang product label practic use flavour chemic addit vape product enact statewid flavour legisl may new york state enact legisl ban sale vape product distinguish flavour tobacco accord new statut vape product deem flavour includ statement whether express impli distinguish tast aroma tobacco studi aim determin manufactur respond
D000072137;D062789;D066300
T055;T073;T131;T109
36,328,466
electron nicotin deliveri system end flavour devic use adult us fda end enforc prioriti find us itc smoke vape survey februari us food drug administr fda prioritis enforc effort flavour prefil cartridgepod electron nicotin deliveri system end except tobacco menthol studi examin chang preprior enforc earli postenforc februari june among adult end flavour devic use often locat last purchas fruitoth flavour cartridg cover enforc prioriti smoke vape
D000072137;D066300;D062789
T055;T073;T131;T109
36,328,465
examin associ e cigarett flavour restrict e cigarett use success quit smoke among us adult restrict avail e cigarett flavour tobacco menthol may reduc appeal among youth unknown flavour restrict impact adult use e cigarett quit smoke cigarett
D066300;D000072137;D016540
T055;T073
36,328,464
industri respons strengthen regul amount theme flavour electron cigarett promot product vendor manufactur instagram social media discuss tend follow news propos enact govern polici thus digit discours surveil may effect unobtrus way understand industri public respons polici regul includ domain tobacco control recent us food drug administr restrict sale flavour cartridg dispos vape product histor tobacco industri use modif product characterist label packag work around flavour restrict aim characteris strategi use nicotin product manufactur vendor promot flavour product instagram identifi polici workaround tactic
D066300;D062789;D000072137;D061108
T073;T109;T131;T055;T170
36,328,463
associ live local e cigarett sale restrict e cigarett use chang among young adult los angel counti local e cigarett sale restrict esr may impact e cigarett use studi examin associ live local various esr polici chang e cigarett use among young adult los angel la counti california usa
D066300;D000072137;D062789;D000073865
T055;T073;T131;T109
36,328,462
flavour loyalti may predict cessat substitut follow cigarillo flavour ban among young adult usa purpos research measur flavour loyalti identifi current cigarillo user may respond hypothet flavour ban usa
D062789;D014029
T131;T048;T073;T109
36,328,461
illeg experiment tobacco marketplac ii effect vape product ban find intern tobacco control project restrict e cigarett polici may increas purchas illeg sourc illeg experiment tobacco marketplac ietm allow examin restrict impact illeg purchas investig effect vape ban total flavour vape ban partial flavour vape ban probabl purchas illeg vape product among differ regulatori environ usa canada england tobacco user type cigarett smoker dual user e cigarett user relat ban endors illeg purchas
D000072137;D066300;D062789
T055;T073;T131;T109
36,328,460
ethyl maltol vanillin corylon convent confectioneri relat flavour chemic domin e cigarett liquid label tobacco flavour increas popular electron cigarett e cigarett link abund flavour product attract adolesc young adult last decad e cigarett design evolv four generat includ modif batteri power e cigarett liquid e liquid reservoir atomis unit e liquid likewis evolv term solvent useratio concentr number flavour chemic use nicotin salt acid recent increas use synthet cool agent introduct synthet nicotin current object evalu compar evolv composit tobacco flavour e liquid last year
D066300;D062789
T131;T073;T109
36,328,459
electron cigarett user reaction respons hypothet ban flavour electron cigarett liquid backgroundregul propos limit e cigarett flavour limit research examin potenti impact polici studi examin adult e cigarett user reaction hypothet e cigarett flavour ban
D066300;D000072137;D062789
T055;T073;T131;T109
36,328,458
juul alter content menthol pod respons us fda flavour enforc polici juul electron cigarett e cigarett remain popular usa big preval among youth respons popular juul similar devic among youth us food drug administr issu februari enforc polici remov flavour cartridgepod base e cigarett market except tobacco menthol subsequ studi show user remov flavour juul pod especi cool mint switch menthol flavour juul pod similar satisfact
D066300;D062789;D000072137
T131;T073;T055;T109
36,328,457
impact fda flavour enforc polici flavour electron cigarett use behaviour chang studi aim investig electron cigarett e cigarett use behaviour chang implement us food drug administr fda restrict sale unauthoris flavour cartridg base e cigarett tobacco menthol flavour februari well factor associ chang
D066300;D000072137;D062789
T055;T073;T131;T109
36,328,456
assess toxic emiss e liquid diy addit use respons potenti flavour ban e cigarett electron cigarett e cigarett aerosolis liquid contain nicotin propylen glycol glycerol appeal flavour usa regul limit avail flavour e cigarett pod base system tighten expect respons e cigarett user may attempt make e liquid diy studi examin toxic emiss sever aerosolis diy e liquid
D066300
T073
36,328,435
role red blood cell immun respons infect review red blood cell largest number cell blood apart transport oxygen carbon dioxid also regul immun respons confirm red blood cell play role clear immun complex promot phagocytosi present antigen immun adhesionthey also regul immun respons particip oxid stress interact lymphocyt furthermor pathogen invad host exert anti infect immun respons also induc inflammatori respons caus seri immunopatholog injuri may bring chang red blood cell matur process morpholog function review summar recent progress role mechan red blood cell anti infecti immun provid theoret basi reveal pathogenesi explor therapeut target
D010587;D008214
T025;T043
36,328,434
regul pd l posttransl modif applic progress tumor immunotherapi immun checkpoint program death ligand program death pd lpd one promis target tumor immunotherapi overexpress pd l surfac tumor cell could bind pd surfac cell inhibit cell activ trigger tumor immun escap therapeut strategi target pd pd l restor cytotox function immun cell tumor block pd pd l interact pd l undergo multi level regul tumor cell among post translat modif ptms pd l main includ glycosyl phosphoryl ubiquitin acetyl palmitoyl attract much attent recent year modif direct affect stabil cellular local function pd l subsequ regul cell activ tumor immun therefor intervent ptms pd l may serv new approach anti tumor immun escap therapi
D060890;D009369
T129;T191;T116
36,328,433
prokaryot express prostat specif membran antigen psma nanoantibodi gene screen natur phage nanoantibodi librari object screen nanobodi prostat specif membran antigen psma method base naiv phage display librari three round screen perform target psma antigen posit clone identifi elisa sequenc perform posit clone gene sequenc insert peta prokaryot express vector transform ecoli bl express recombin protein induc iptg purifi use ni column purifi product verifi sds page result four psma nanobodi vhh vhh vhh vhh obtain screen vhh fail obtain protein express vhh vhh vhh protein express puriti anti psma nanobodi show high relat molecular mass r conclus sequenc anti psma nanobodi success obtain screen naiv phage nanobodi librari subject prokaryot express purifi
D061905;D001435
T129;T005;T116
36,328,432
unsatur fatti acid actinidia chinesi planch seed oil protect pulmonari fibrosi inhibit collagen synthesi via regul connect tissu growth factor ctgf express rat object observ role connect tissu growth factor ctgf collagen synthesi anti pulmonari fibrosi pf kiwi fruit essenc unsatur fatti acid actinidia chinesi planch seed oil rat method sixti male sd rat random divid control group model group kiwi fruit essenc mgkg treatment group mgkg prednison acet group anim group rat control group intratrach administ gl sodium chlorid solut anim group intratrach administ bleomycin establish pf model second day rat latter group intragastr treat kiwi fruit essenc mgkg prednison acet mgkg respect rat control model group treat gl sodium chlorid solut day rat sacrif day pulmonari tissu remov extent pf lesion evalu use masson stain content hydroxyprolin hyp measur commerci kit mrna express ctgf smooth muscl actin sma pulmonari tissu detect quantit real time pcr protein express ctgf sma collagen type col col measur western blot protein level ctgf analyz use immunohistochem stain result compar model group alveol pf extent mgkg kiwi fruit essenc treatment group well mgkg prednison acet group signific allevi content hyp express ctgf sma col col decreas chang indic dose depend among mgkg kiwi fruit essenc treatment group moreov indic found higher mgkg kiwi fruit essenc treatment group mgkg prednison acet group howev show signific differ mgkg kiwi fruit essenc treatment group mgkg prednison acet group conclus kiwi fruit essenc regul ctgf express decreas level sma lead inhibit col col synthesi allevi pf
D029042;D011658;D009822
T047;T002;T109
36,328,431
silenc circular rna embryon lethal abnorm vision like protein circelavl inhibit prolifer induc apoptosi mous testicular tm sertoli cell object investig effect silenc circular rnaembryon lethal abnorm vision like protein circelavl mmucirc prolifer apoptosi mous testicular tm sertoli cell identifi under mechan method small interf rnas sirna use silenc express circelavl tm cell cck assay ethynyl deoxyuridin edu assay use detect effect circelavl prolifer tm cell flow cytometri tdt mediat dutp nick end label tunel use detect effect circelavl apoptosi tm cell bioinformat adopt predict potenti bind site circealvl mir p luciferas report assay detect bind abil circelavl mir p real time quantit polymeras chain reaction rt qpcr use detect express level circelavl mir p result silenc express circelavl prolifer rate proport edu posit tm cell decreas apoptot level tm cell increas mechan studi found circelavl could bind mir p inhibit express conclus circelavl promot cell prolifer suppress cell apoptosi mous tm sertoli cell bind inhibit mir p
D000079962;D035683
T123;T114
36,328,430
regul mir inhibit mitochondri fusion fission rat hc cardiomyocyt induc oxygen glucos deprivationreoxygen object investig effect mir interfer mitochondri fusion fission cardiomyocyt induc oxygen glucos deprivationreoxygen ogdr method hc cell divid normal control group model group negat control group mir interfer group rat hc cardiomyocyt injuri model induc ogdr negat control nc group cell transfect anti nc mir interfer group cell transfect anti mir normal control group cell transfect revers transcript pcr use detect mir interfer effici along cck assay detect cell prolifer ratio flow cytometri detect cell apoptosi rate mitochondri membran potenti chang kit detect superoxid dismutas sod malondialdehyd mda lactat dehydrogenas ldh content western blot analysi employ test level bcl associ x protein bax bcl antagonistkil bak caspas mitochondri fission protein fis mitofusin mfn mfn optic atrophi opa phosphoryer extracellular signal regul kinas p erk phosphoryer dynamin relat protein p drp result compar ogdr group express level mir hc cell ogdr group treat anti mir decreas signific togeth find includ signific increas cell prolifer factor decreas apoptosi rate increas sod content decreas mda ldh content well signific increas mitochondri membran potenti protein level bax bak caspas fis mfn mfn opa p erk p drp signific decreas conclus interfer mir express promot ogdr induc prolifer hc cell inhibit cell apoptosi reduc mitochondri oxid stress level enhanc mitochondri membran potenti allevi mitochondri fusion fission myocardi cell
D032383;D035683
T123;T025;T114
36,328,429
wnta activ jnk promot prolifer autophagi kgn human granulosa cell object investig effect wnta autophagi kgn human granulosa cell method kgn human granulosa cell treat dmso control group recombin wnta protein rwnta wnta inhibitor iwp box separ express level wnta protein detect western blot co local wnta protein forkhead box l foxl specif marker granulosa cell observ immunofluoresc cytochem stain rwnta group iwp group prolifer kgn cell detect cck assay effect rwnta iwp autophagi kgn cell express c jun n termin kinas jnk nuclear factor activ cell nfat protein detect western blot result compar control group express wnta protein rwnta group increas cell prolifer promot express microtubul associ protein light chain lc jnk nfat increas express nucleoporin p protein decreas contrast rwnta group express wnta protein decreas cell prolifer inhibit express lc jnk nfat protein decreas express p protein increas iwp group conclus wnta promot prolifer autophagi kgn human granulosa cell activ jnk
D001343;D006107
T025;T043
36,328,428
eukaryot express human box bind protein yb promot prolifer migrat human hepg cell object establish eukaryot express vector box bind protein yb flag tag transfect hepatocellular carcinoma hepg cell identifi effect yb prolifer migrat method human yb gene amplifi human ovari librari pcr yb fraction doubl enzym digest connect pcdna flag vector construct eukaryot express vector pcdna flag yb transfect hepg cell express yb detect western blot effect yb prolifer hepg cell determin cck assay clone format effect yb migrat hepg cell analyz wound heal assay result eukaryot express vector pcdna flag yb success establish yb protein express hepg cell yb promot prolifer migrat hepg cell conclus yb promot prolifer migrat hepg cell
D051840;D056890
T123;T116;T204
36,328,427
astragalosid iv inhibit oxid stress mediat apoptosi human syy cell activ nrf ho signal pathway object investig protect effect mechan astragalosid iv ast h induc oxid stress injuri apoptosi syy cell method human syy cell cultur vitro induc h establish oxid stress model divid pbs group h group ast group cell viabil determin mtt assay cell apoptosi detect termin deoxynucleotidyl transferas mediat dutp biotin nick end label assay tunel supernat use determin activ malondialdehyd mad superoxid dismutas sod glutathion gsh group immunofluoresc cytochemistri use detect nuclear factor e relat factor nrf cleav caspas c caspas b lymphoblastoma bcl bcl associ x protein bax c caspas nrf cell nuclei heme oxygenas ho determin western blot analysi result ast protect effect viabil syy cell oxid stress damag reduc content mad increas content gsh sod ast increas bcl decreas bax thus bcbax ratio signific increas compar h group meanwhil ast inhibit express c caspas ast promot nuclear transloc nrf increas express downstream antioxid protein ho conclus ast promot nrf nuclear transloc increas ho express regul oxidationantioxid balanc improv antioxid level protect cell oxid damag reduc apoptosi activ nrf ho signal pathway
D051267;D006861
T123;T121;T116;T197;T130
36,328,426
block connexin inhibit polar mous macrophag induc lipopolysaccharid object investig effect connexin cx polar mous raw macrophag induc lipopolysaccharid lps method raw macrophag cultur vitro random divid four group control group lps group lps combin gap group lps combin gap group protein level cx polar marker cd induc nitric oxid synthas ino mous raw macrophag detect western blot analysi express local cd raw macrophag observ immunofluoresc cytochemistri express frequenc polar marker cd mous raw macrophag detect flow cytometri result compar control group protein express cd ino cx well express frequenc cd lps group show signific increas howev compar lps group protein express cd ino express frequenc cd decreas signific lps combin gap group lps combin gap group lps could induc polar macrophag gap gap reduc express polar marker conclus polar macrophag inhibit block cx
D008070;D018031
T123;T116;T109
36,328,425
tolerogen dendrit cell form microchimer vivo collagen induc arthriti rat object find evid microchimer format follow infus tolerogen dendrit cell tdcs collagen induc arthriti cia rat method bone marrow deriv dc precursor cell induc tdcs granulocyt macrophag coloni stimul factor gm csf interleukin il nuclear factor b oligonucleotid decoy nf b odn decoy infus cia rat label octadecyl tetramethyltricarbocyanin iodid dir hour hour day day day cell infus fluoresc intens distribut observ vivo imag system small anim rat sacrif th day detect fluoresc signal main organ result tdcs high express ox low express cd cd fluoresc signal main concentr chest abdomen left posterior joint strongest fluoresc signal chest abdomen hour strongest fluoresc signal left posterior joint day fluoresc could still detect th day cell infus left posterior joint diseas foot alway maintain strong fluoresc signal isol organ fluoresc signal lung liver spleen mesenter lymph node strong kidney fluoresc signal weak heart littl fluoresc conclus tdcs form microchimer diseas foot joint lung liver spleen mesenter lymph node
D001169
T050